drugset / Trial / NCT03180593
Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH
Phase 4
Completed
30 enrolled
Trinity Hypertension & Metabolic Research Institute
Allergan Sales, LLC · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
To assess the efficacy of Left Ventricular Hypertrophy (LVH) reduction and 24-hour blood pressure control of Valsartan 80mg or Nebivolol/Valsartan 5/80mg once daily as replacement therapy for currently treated or untreated hypertensive patients with LVH not at BP goal.
Timeline
- Start
- 2017-02-07
- Primary completion
- 2018-01-25
- Completion
- 2018-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Nebivolol | Other / unclassified | 5 mg | — |
| Comparator | Valsartan | Small molecule | 80 mg | — |